[HTML][HTML] Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community …
Background The protective immunity against omicron following a BNT162b2 Pfizer booster
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
[HTML][HTML] Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community …
T Bruel, L Pinaud, L Tondeur, D Planas… - …, 2022 - ncbi.nlm.nih.gov
Background The protective immunity against omicron following a BNT162b2 Pfizer booster
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
[HTML][HTML] Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community …
T Bruel, L Pinaud, L Tondeur, D Planas, I Staropoli… - eClinicalMedicine, 2022 - Elsevier
Background The protective immunity against omicron following a BNT162b2 Pfizer booster
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based …
T Bruel, L Pinaud, L Tondeur, D Planas… - …, 2022 - anr.hal.science
BACKGROUND: The protective immunity against omicron following a BNT162b2 Pfizer
booster dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
booster dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based …
T Bruel, L Pinaud, L Tondeur, D Planas… - …, 2022 - u-picardie.hal.science
BACKGROUND: The protective immunity against omicron following a BNT162b2 Pfizer
booster dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
booster dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based …
T Bruel, L Pinaud, L Tondeur, D Planas… - …, 2022 - europepmc.org
Background The protective immunity against omicron following a BNT162b2 Pfizer booster
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based …
T Bruel, L Pinaud, L Tondeur, D Planas… - …, 2022 - inria.hal.science
BACKGROUND: The protective immunity against omicron following a BNT162b2 Pfizer
booster dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
booster dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based …
T Bruel, L Pinaud, L Tondeur, D Planas… - …, 2022 - cnam.hal.science
BACKGROUND: The protective immunity against omicron following a BNT162b2 Pfizer
booster dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
booster dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
[PDF][PDF] Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community …
T Bruel, L Pinaud, L Tondeur, D Planas, I Staropoli… - 2022 - scienceopen.com
Background The protective immunity against omicron following a BNT162b2 Pfizer booster
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based …
T Bruel, L Pinaud, L Tondeur, D Planas, I Staropoli… - …, 2022 - hal.science
BACKGROUND: The protective immunity against omicron following a BNT162b2 Pfizer
booster dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
booster dose among elderly individuals (ie, those aged> 65 years) is not well characterised …